Agenus Inc. — Form 10-Q Summary
Business context and reporting period
Immuno-oncology company developing checkpoint-modulator antibodies, heat-shock-protein vaccines and vaccine adjuvants. This unaudited report covers the quarter and six months ended June 30, 2014; it was filed August 1, 2014. The February acquisition of 4-Antibody AG added the Retrocyte Display antibody-discovery platform and six preclinical checkpoint-modulator programs.
Financial results and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $3.07 million | $0.81 million | $3.79 million | $1.92 million |
| Operating loss | $8.22 million | $7.33 million | $18.32 million | $11.94 million |
| Net loss | $7.76 million | $11.14 million | $8.40 million | $16.98 million |
| Net loss attributable to common stockholders | $7.81 million | $11.19 million | $8.50 million | $20.03 million |
| Basic and diluted loss per share | $0.12 | $0.40 | $0.15 | $0.76 |
- At June 30, cash and cash equivalents were $48.27 million and short-term investments were $14.55 million, totaling $62.82 million. Total assets were $100.19 million; accumulated deficit was $657.22 million.
- Operating cash use was $19.62 million in the first half, versus $9.56 million in the comparable 2013 period. Investing cash use was $14.80 million; financing provided $55.19 million, primarily from equity issuance. Cash increased $20.92 million during the half.
- Debt was $7.43 million on the balance sheet, all current; the filing separately reports $7.9 million principal outstanding at June 30. The SVB loan and subordinated notes mature in April 2015.
- Current assets were $67.03 million and current liabilities $18.57 million. Deferred revenue totaled $5.63 million. Contingent royalty and acquisition purchase-price liabilities were $7.36 million and $10.85 million, respectively.
Material changes versus comparable periods
- First-half revenue nearly doubled, reflecting license, grant and milestone-related revenue; however, operating loss widened as research and development and general and administrative expenses increased. First-half R&D rose to $9.70 million from $5.87 million, and G&A to $11.29 million from $7.53 million, in part due to 4-Antibody and higher personnel and professional costs.
- First-half net loss improved year over year, largely because non-operating income included a $11.44 million reduction in the fair value of the contingent royalty obligation. That revaluation was primarily associated with GSK ending a Phase 3 cancer-vaccine trial. It is a noncash valuation item, not operating revenue.
- February’s public offering of 22.24 million shares generated approximately $56.2 million net proceeds. Common shares outstanding rose to 62.65 million at June 30 from 36.39 million at year-end 2013.
Outlook, management commentary and risks
- Management stated that cash, cash equivalents and short-term investments, together with potential receipts under existing agreements, were expected to fund liquidity needs through the first half of 2015. The company expected to seek additional funding before exhausting available resources and could pursue partnerships, asset sales, debt or equity financing, and spending reductions. It warned that failure to obtain capital could threaten continued operations.
- During Q2, Agenus entered a Merck collaboration to discover and optimize antibodies against two undisclosed cancer targets. Merck is responsible for development and commercialization; Agenus may receive approximately $100 million in potential milestone payments plus royalties. These are contingent potential amounts, not guaranteed revenue.
- Management planned to identify development candidates for four additional checkpoint-modulator programs in the second half of 2014 and sought to be positioned to file INDs on at least four candidates within two years. The programs were preclinical.
- The company reported positive Phase 2 HerpV immune-response and viral-shedding findings and was seeking a development partner; further development and clinical benefit remained uncertain. A July 2014 announcement about Prophage results was made after the reporting period; the filing cautions that development prospects remain uncertain.
- GSK submitted a European marketing application for its malaria vaccine containing QS-21 in June. Partner trial outcomes, approvals, product launches and royalties remain uncertain; the filing also describes the termination of a GSK Phase 3 lung-cancer vaccine trial.
- Key risks include recurring losses and cash burn, dependence on external financing and collaborators, clinical and regulatory uncertainty, manufacturing and acquisition-integration challenges, intellectual-property and competition risks, and foreign-currency exposure. The NewVac Oncophage license was expected to end in December 2014. Management reported effective disclosure controls and no material second-quarter change in internal control; integration of 4-Antibody controls was ongoing.
Important facts for investors to verify
- Whether actual cash burn, partner receipts and financing availability support the stated runway through the first half of 2015.
- The terms, milestones and economics of the Merck collaboration, and whether any contingent payments become probable or are received.
- Clinical-trial progress, partner decisions and regulatory outcomes for HerpV, Prophage and QS-21 programs, including the effect of GSK trial decisions.
- The final 4-Antibody purchase-price allocation, subsequent valuation changes in contingent liabilities, and integration progress.
- Debt repayment and covenant requirements, potential dilution from shares and equity-linked awards, and the status of the NewVac license.